WESTON, Mass. & CARLSBAD, Calif.–(BUSINESS WIRE)–Jun. 29, 2012– Biogen Idec (NASDAQ: BIIB) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that they have entered into an exclusive, worldwide option and collaboration agreement under which the companies will develop and commercialize a novel antisense drug for the treatment of myotonic dystrophy type 1 (DM1), which is also known as Steinert disease. (from press release)
Read full article here, including details about funding amounts that could reach $200M!
